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Summary  Obesity  is  deﬁned  as  abnormal  or  excessive  fat  accumulation.  Chronic  inﬂammation
in fat  inﬂuences  the  development  of  obesity-related  diseases.  Many  reports  state  that  obesity
increases the  risk  of  morbidity  in  many  diseases,  including  hypertension,  dyslipidemia,  type  2
diabetes, coronary  heart  disease,  stroke,  sleep  apnea,  and  breast,  prostate  and  colon  cancers,
leading to  increased  mortality.  Obesity  is  also  associated  with  chronic  neuropathologic  condi-
tions such  as  depression  and  Alzheimer’s  disease.  However,  there  is  strong  evidence  that  weight
loss reduces  these  risks,  by  limiting  blood  pressure  and  improving  levels  of  serum  triglyceri-
des, total  cholesterol,  low-density  lipoprotein  (LDL)-cholesterol,  and  high-density  lipoprotein
(HDL)-cholesterol.  Prevention  and  control  of  obesity  is  complex,  and  requires  a  multifaceted
approach.  The  elucidation  of  molecular  mechanisms  driving  fat  metabolism  (adipogenesis  and
lipolysis) aims  at  developing  clinical  treatments  to  control  obesity.  We  recently  reported  a  new
regulatory  mechanism  in  fat  metabolism:  a  protein  phosphatase  binding  protein,  phospholipase
C-related catalytically  inactive  protein  (PRIP),  regulates  lipolysis  in  white  adipocytes  and  heat
production  in  brown  adipocytes  via  phosphoregulation.  Deﬁciency  of  PRIP  in  mice  led  to  reduced
fat accumulation  and  increased  energy  expenditure,  resulting  in  a  lean  phenotype.  Here,  we
evaluate  PRIP  as  a  new  therapeutic  target  for  the  control  of  obesity.
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1. Introduction
The  World  Health  Organization  points  out  that  obesity  is  cur-
rently  one  of  the  most  blatantly  visible,  yet  most  neglected,
public  health  problem.  If  immediate  action  is  not  taken,
millions  will  suffer  from  an  array  of  serious  health  disorders
linked  to  obesity  [1].  Recent  studies  have  demonstrated  that
obesity  is  associated  with  some  of  the  cellular  mechanisms
of  inﬂammation  and  overproduction  of  proinﬂammatory
cytokines.  The  pathological  conditions  of  adipose  tissue
under  hypertrophy  (cell  size  increase)  and  hyperplasia  (cell
number  increase)  are  low-grade  and  chronic  inﬂammation
may  lead  to  the  development  of  various  co-morbidities,  such
as  hypertension,  dyslipidemia,  type  2  diabetes,  coronary
heart  disease,  stroke,  and  cancers  [2,3].
Inﬂammation  is  a  physiological  response  necessary  to
restore  homeostasis  altered  by  diverse  stimuli;  however,  an
excessive  inﬂammatory  response  or  a  chronically  established
inﬂammation  state  can  cause  systemic  deleterious  effects.
For  instance,  periodontal  disease  is  a  source  of  chronic
inﬂammation  and  was  found  to  play  a  causative  or  con-
tributory  role  in  the  pathogenesis  of  systemic  diseases  [4].
Furthermore,  epidemiological  studies  have  recently  shown
high  co-morbidity  between  mental  illness  and  peripheral
chronic  inﬂammatory  diseases,  including  obesity  and  peri-
odontitis  [2—4].  Therefore,  the  control  of  inﬂammation  in
peripheral  organ  diseases  is  paramount  for  the  protection
and  promotion  of  human  health.
Adipose  tissues  are  an  insidious  source  of  inﬂammation  in
morbid  obesity.  We  have  elucidated  a  new  regulatory  mech-
anism  in  lipid  and  energy  metabolisms  within  adipocytes  to
control  obesity.  Phospholipase  C-related  catalytically  inac-
tive  protein  (PRIP),  a  new  functional  molecule  in  lipolysis,
is  involved  in  a  triacylglycerol  (TAG)  degradation  pathway
via  intracellular  phosphoregulation.  Here,  we  discuss  the
regulation  of  TAG  hydrolysis  via  PRIP.
2. Fat metabolism in adipocytes
antagonistic  functions  [5]. WAT  is  the  major  energy  stor-
age  component  in  higher  eukaryotes.  The  primary  purposes
of  this  tissue  are  synthesis  and  storage  of  TAG  in  periods
of  energy  excess,  and  hydrolysis  of  TAG  to  generate  fatty
acids  for  use  by  other  organs  during  periods  of  energy  depri-
vation.  In  contrast,  BAT  directly  dissipates  the  chemical
energy  contained  in  fatty  acids  as  heat  via  uncoupling  pro-
tein  1  (UCP1)  as  a  defense  against  cold  and  excessive  feeding
(Fig.  1).  Understanding  of  molecular  mechanisms  driving
adipocyte-speciﬁc  TAG  synthesis  and  hydrolysis,  and/or  gov-
erning  energy  expenditure  in  brown  adipocytes  is  critical  to
explain  the  development  of  obesity.
2.2.  Activation  of  lipolysis  by  catecholamine
signaling
Although  TAG  synthesis  occurs  in  multiple  tissues,  TAG  lipol-
ysis  during  periods  of  energy  demand  predominantly  occurs
in  adipose  tissues.  The  hydrolytic  action  by  lipases  in  WAT
is  rapid,  and  free  fatty  acids  (FFAs)  are  supplied  to  other
organs  to  meet  the  energy  requirements  of  the  organism
[6]. The  TAG  degradation  process  is  regulated  by  several
molecules,  including  anti-comparative  gene  identiﬁcation
58  (CGI-58),  perilipin  (lipid  droplet-associated  protein),  and
the  lipolytic  enzymes,  adipocyte  triglyceride  lipase  (ATGL),
hormone-sensitive  lipase  (HSL),  and  monoacylglycerol  lipase
(MGL).  These  lipolytic  enzymes  and  modulators  promote  the
hydrolysis  of  TAG,  resulting  in  the  formation  of  FFAs  and
glycerol  in  adipocytes  (Fig.  1).
The  intracellular  degradation  of  TAG  is  catalyzed  by  a
cascade  of  lipolytic  enzymes  (Fig.  2).  Under  basal  condition,
at  the  surface  of  lipid  droplets,  perilipin,  a  master  lipolysis
regulator  of  stored  TAG,  sequesters  CGI-58,  a  coactivator
protein  of  ATGL  [7].  This  prevents  sequential  hydrolysis
of  stored  TAG.  Under  starvation  conditions,  sympathetic
nerves  are  activated,  which  initiates  adipose  lipolysis.
Catabolic  hormone  adrenaline,  a  catecholamine,  binds  to
-adrenergic  receptors  on  adipocyte  plasma  membrane  and
triggers  a  G  protein-mediated  cascade  that  activates  adeny-2.1.  Regulation  of  fat  metabolism
There  are  two  types  of  adipose  tissues,  white  adipose  tis-
sue  (WAT)  and  brown  adipose  tissue  (BAT),  which  have
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fate  cyclase,  which  itself  increases  levels  of  cAMP  and
ctivates  protein  kinase  A  (PKA).  PKA  phosphorylates  per-
lipin  at  multiple  sites.  Subsequently,  CGI-58  is  released
rom  perilipin,  associates  with,  and  fully  activates  ATGL.
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Figure  1  Fat  metabolism  in  adipocytes.  WAT  is  the  primary  energy  storage  depot,  accumulating  fuel  reserves  in  the  form  of  TAG
during times  of  energy  excess,  and  releasing  FFAs  and  glycerol  during  periods  of  energy  deprivation.  BAT  is  specialized  in  dissipating
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hemical energy  in  the  form  of  heat  via  UCP1,  which  is  activate
rown adipose  tissue;  TAG,  triacylglycerol;  FFA,  free  fatty  acid
his  ATGL  hydrolyzes  TAG  into  diacylglycerol  (DAG).  The
ctivated  PKA  also  phosphorylates  HSL,  located  in  the  cyto-
ol.  Phosphorylated  HSL  is  translocated  from  the  cytosol  to
he  surfaces  of  intracellular  lipid  droplets  and  is  tethered
n  the  lipid  droplets  by  the  phosphorylated  perilipin.  Sub-
equently,  activated  (phosphorylated)  HSL  hydrolyzes  DAG
nto  monoacylglycerol,  followed  by  degradation  into  a  FFA
nd  glycerol  by  MGL  in  the  ﬁnal  step  of  lipolysis.  FFAs  are
eleased  into  the  blood  stream,  where  they  bind  to  albumin
or  transport  to  surrounding  tissues  requiring  energy.  Glyc-
rol  is  also  transported  into  the  bloodstream  and  is  absorbed
y  the  liver  or  kidneys,  where  it  is  converted  to  glycerol
-phosphate  by  the  enzyme  glycerol  kinase.
Perilipin  is  phosphorylated  at  multiple  sites  by  PKA,  a  pro-
ess  essential  for  the  translocation  of  HSL  to  lipid  droplets.
urthermore,  this  response  corresponds  to  the  phosphoryla-
ion  of  HSL  and  the  acceleration  of  lipolysis  promoted  by  the
ympathetic  nervous  system  in  adipocytes.  HSL  can  be  phos-
horylated  at  least  on  ﬁve  serine  residues  (563,  565,  600,
59,  and  660  of  the  rat  sequence)  in  vitro  [7].  Ser-563,  Ser-
59,  and  Ser-660  are  the  major  PKA  phosphorylation  sites
esponsible  for  activating  HSL.  Dephosphorylation  of  HSL  and
erilipin  by  protein  phosphatases  can  also  play  an  important
ole  in  the  regulation  of  lipolysis.
.3.  Inhibition  of  lipolysis  by  insulin  receptor
ignaling
nsulin,  the  major  anabolic  hormone,  can  restrain  lipoly-
is  and  promote  fat  storage  in  adipose  tissues  during  the
ostprandial  period.  Protein  phosphatases  are  involved  in
he  antilipolytic  effect  of  insulin.  Insulin  receptor  tyrosine
inase  phosphorylates  insulin  receptor  substrate  (IRS)-1,
hich  recruits  and  activates  phosphoinositide  3-kinase
PI3K)  leading  to  the  production  of  phosphatidylinositol-
,4,5-triphosphate  (PIP3).  AKT  (also  known  as  protein  kinase
A
a
c
Isympathetic  nerve  stimulation.  WAT,  white  adipose  tissue;  BAT,
1,  uncoupling  protein  1;  GLUT4,  glucose  transporter  4.
)  is  recruited  onto  the  membrane  by  binding  with  PIP3 via
ts  pleckstrin  homology  domain,  and  is  subsequently  phos-
horylated  and  activated  by  PDK1.  AKT  thus  phosphorylates
wo  important  targets,  phosphodiesterase  3B  [8]  and  protein
hosphatases  (protein  phosphatase  1,  protein  phosphatase
A,  and  protein  phosphatase  2C)  [9,10],  to  allow  the  down-
egulation  of  lipolysis.  Consequently,  lipolysis  in  adipocytes
s  attenuated.  In  addition,  insulin  signaling-independent
ephosphorylation  of  HSL  and  perilipin  may  be  involved  in
he  inactivation  of  lipolysis  after  activation  of  the  sympa-
hetic  nervous  system;  however,  this  mechanism  has  not  yet
een  elucidated.
. A new molecule for the regulation of
ipolysis  in adipocytes
.1.  Identiﬁcation  of  PRIP
RIP  was  originally  puriﬁed  as  an  inositol  1,4,5-trisphosphate
Ins(1,4,5)P3]  binding  protein  from  the  cytosol  fraction  of
he  rat  brain,  but  has  since  been  isolated  from  the  mem-
rane  fraction  of  the  brain  [11,12].  PRIP  has  similar  domain
rganization  to  phospholipase  C-1  [13,14],  but  lacks  the
nzymatic  activity  of  phospholipase  C  [15]  (Fig.  3).  There
re  two  isoforms  in  mammals;  PRIP1,  expressed  mainly  in  the
rain,  and  PRIP2,  ubiquitously  expressed  [16,17].  Both  PRIPs
re  expressed  in  white  and  brown  adipose  tissues  [18,19].
xperiments  exploring  a  PRIP  binding  partner  revealed  that
RIP  can  bind  to  PP1  and  PP2A  [20—25],  Ins(1,4,5)P3 and
nositol  lipids  [11,12,26—28], gamma  aminobutyric  acid
ype  A  receptor-associated  protein  (GABARAP)  [29—33],
 subunit  of  GABAA receptor  [21], and  phosphorylated
KT  [34]. After  verifying  the  relationship  between  PRIP
nd  these  binding  partners  using  Prip-KO  mice,  we  elu-
idated  the  role  of  PRIP  in  cells;  PRIP  is  involved  in
ns(1,4,5)P3/Ca2+ signaling  [35,36], dephosphoregulation  of
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Figure  2  Possible  mechanism  by  which  the  PRIP  and  protein-
phosphatase  complex  mediates  lipolysis  regulation.  Lipolysis  in
adipocytes  is  mediated  by  the  activation  of  a  PKA-mediated
pathway.  The  process  is  regulated  by  lipases  (HSL  and  ATGL)
and other  modulatory  proteins,  including  perilipin,  CGI-58,
PP2A, and  PRIP.  Phosphorylation  of  perilipin  releases  CGI-
58, resulting  in  the  activation  of  ATGL  by  association  with
CGI-58.  Phosphorylated  HSL  is  translocated  to  the  lipid  mem-
brane  and  degrades  TAG  and/or  DAG.  These  events  are  also
regulated  by  phosphatases  (PP1  and  PP2A),  whose  activities
are modulated  by  PRIP.  The  disappearance  of  the  dotted
line represents  postulated  situations  in  Prip-DKO  mice.  AC,
adenylate  cyclase;  ATGL,  adipocyte  triglyceride  lipase;  TAG,
triacylglycerol;  FFA,  free  fatty  acid;  P,  phosphate  group;  PKA,
protein  kinase  A;  HSL,  hormone-sensitive  lipase;  PRIP,  phospho-
lipase  C-related  catalytically  inactive  protein;  PP2A,  protein
Figure  3  Phospholipase  C-related  catalytically  inactive  pro-
tein. PRIP  has  a  similar  domain  organization  to  PLC1.  The
binding partners  of  PRIP  are  shown.  The  numbers  represent
amino acid  residues.  IP3,  inositol  1,4,5-trisphosphate;  PP1,  pro-
tein phosphatase  1;  PP2A,  protein  phosphatase  2A;  GABARAP,
GABAA receptor-associated  protein;  GABAAR  ,  GABAA receptor
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intracellular  signaling  molecules  [18,19,21,22],  intracellular
trafﬁcking  of  GABAA receptors  or  insulin  secretory  vesicles
[29,30,33,37—40],  and  regulation  of  autophagy  [31,32].
3.2.  Lean  phenotype  of  Prip-KO  mice
Studies  in  Prip-null  knockout  (Prip-KO)  mice  have  conﬁrmed
the  importance  of  this  molecule  in  the  lipolysis  of  TAG
[18,19].  Regular  diet  (RD)-fed  Prip-KO  mice  exhibited  a  lean
phenotype  with  smaller  WAT  in  size  and  weight.  The  Prip-
KO  mice  showed  slightly  more  food  intake  than  wild-type
mice.  The  serum  cholesterol  and  TAG  levels  were  signiﬁ-
cantly  increased  in  Prip-KO  mice  compared  with  wild-type
control  mice.  However,  ectopic  lipid  accumulation  was  not
observed  in  the  liver  of  Prip-KO  mice.  In  high-fat  diet  (HFD)-
feeding  experiments,  Prip-KO  mice  showed  less  body  weight
increase,  and  their  body  weight  at  20  weeks  of  age  was
lower  than  that  of  wild-type  controls.  The  Prip-KO  mice
obviously  displayed  leanness  with  small-sized  WAT.  These
results  allowed  associating  the  lean  phenotype  of  Prip-KO
mice  with  the  alteration  of  fat  metabolism  in  adipocytes.
a
P
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H subunit;  PH,  pleckstrin  homology  domain;  EF,  EF  hand  domain;
 and  Y,  catalytic  subunit  of  PLC;  C2,  C2  domain.
.3.  PRIP  and  protein  phosphatase  regulate
drenaline-induced  lipolysis  in  adipocytes
ur  investigations  showed  that  phosphorylation  of  HSL  and
erilipin  in  RD-fed  Prip-KO WAT  was  upregulated  under  both
on-fasting  and  fasting  conditions  compared  with  wild-type
ice.  In  response  to  adrenaline  stimulation,  or  under  starva-
ion  conditions,  the  cytosolic  protein  PRIP  was  translocated
o  lipid  droplets  in  mouse  white  adipocytes;  in  the  mean-
ime,  levels  of  PP1  and  PP2A,  which  bind  to  PRIP,  were
ncreased  in  the  lipid  droplet  fractions  (Fig.  2).  Consistently,
fter  adrenaline  stimulation,  time-dependent  dephosphory-
ation  change  of  HSL  was  observed  in  wild-type  adipocytes,
ut  not  in  Prip-KO adipocytes.  From  these  ﬁndings,  we
roposed  a  model  of  PRIP-mediated  phosphoregulation  of
ipolysis  in  adipocytes  (Fig.  2).  Once  starvation  or  stress
ignals  trigger  the  activation  of  PKA  in  adipocytes,  HSL  is
hosphorylated,  translocated  to  lipid  droplets,  and  activates
ydrolysis  of  lipids.  The  signal  also  induces  the  translo-
ation  of  PRIP  and  protein  phosphatase  complex  to  lipid
roplets,  which  promotes  the  dephosphorylation  of  HSL  and
ttenuates  lipolysis.  These  sequential  events  yield  a  sharp
ransient  activation  of  lipolysis  to  provide  a  ﬁne-tuning  of
atabolic  hormonal  regulation  in  adipocytes.
.4.  PRIP  regulates  energy  metabolism
ompared  to  wild-type  mice,  HFD-fed  Prip-KO mice  showed
ore  moderate  body  weight  increase,  greater  glucose
olerance,  and  higher  insulin  sensitivity.  This  underlined
 protection  mechanism  against  HFD-induced  obesity  in
rip-KO  mice  [19]. Histological  analyses  showed  that  ectopic
ipid  accumulation  in  the  liver  was  strongly  decreased  in
FD-fed  Prip-KO mice.  Consistently,  energy  expenditure  and
22  
Figure  4  PRIP  regulates  thermogenesis  in  brown  adipocytes.
Sympathetic  nerve  stimulation  enhances  receptor-mediated
PKA activation  in  brown  adipocytes.  PKA  induces  UCP1  acti-
vation  through  at  least  two  pathways.  (i)  PKA  facilitates  the
phosphorylation  of  HSL  and  perilipin,  which  promotes  lipolysis.
The resulting  FFAs  enhance  UCP1  enzymatic  activation  and  Ucp1
gene expression  through  PPAR-mediated  PGC1  activation  (the
pathway  represented  by  the  solid  arrows).  (ii)  PKA  also  induces
phosphorylation  of  CREB  and  p38  MAPK,  which  activate  PGC1
and DIO2.  Consequently,  Ucp1  gene  expression  and  activity  are
elevated.  Prip  gene  ablation  (dotted  line)  leads  to  elevation
of HSL  phosphorylation-mediated  lipolytic  cascades  followed
by FFA-mediated  UCP1-induced  heat  production.  CREB,  cAMP
response  element-binding  protein;  DIO2,  type  II  iodothyronine
5′-deiodinase;  Encircled  Ps,  phosphoproteins;  FFA,  free  fatty
acid; HSL,  hormone-sensitive  lipase;  PKA,  cAMP-dependent
protein  kinase;  p38-MAPK,  p38  mitogen-activated  protein
kinase;  PGC1,  peroxisome  proliferator-activated  receptor  
co-activator  1;  PPase,  protein  phosphatase;  PPAR,  peroxisome
proliferator-activated  receptor;  PRIP,  phospholipase  C-related
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tatalytically  inactive  protein;  TAG,  triglyceride;  UCP1,  uncou-
ling protein  1.
ody  temperature  were  higher  in  Prip-KO  mice  than  in  wild-
ype  mice.
Many  studies  have  shown  that  BAT  contributes  to  adult
uman  obesity,  and  activation  of  UCP1-mediated  thermo-
enesis  in  BAT  prevents  obesity  and  diabetes  [5,41,42].
rown  adipocytes  directly  dissipate  the  chemical  energy  in
atty  acids  as  heat  through  uncoupling  protein  1  (UCP1)
Fig.  4).  In  both  white  and  brown  adipocytes,  sympa-
hetic  hyperactivity  causes  -adrenergic  receptor-induced
KA  activation,  followed  by  activation  of  lipolysis.  FFAs
re  used  not  only  as  substrates  for  oxidative  respiration
ut  also  as  allosteric  activators  of  UCP1.  In  addition,  PKA
ctivation  followed  by  elevated  intracellular  FFAs  activates
CP1-mediated  heat  generation  and  regulates  thermogene-
is  through  transcriptional  control  in  BAT  [19,43—45]. PKA
ediates  the  phosphorylation  of  cAMP  response  element-
inding  protein  (CREB)  and  p38  mitogen-activated  protein
inase  (p38  MAPK),  followed  by  activation  of  the  gene
xpression  of  peroxisome  proliferator-activated  receptor
PPAR)-,  coactivator-1 (PGC1), PPAR, and  PPAR, to
nally  trigger  Ucp1  gene  expression  in  brown  adipocytes
d
t
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5,45—47]. The  Prip-KO  mouse  study  demonstrated  that  PRIP
egulates  -adrenergic  receptor  signaling-induced  UCP1-
ependent  thermogenesis  in  BAT  through  phosphoregulation
f  HSL  and  perilipin.
. Chronic peripheral inﬂammation is a  risk
actor  for mental illness
besity  is  a  chronic  inﬂammatory  state  that  originates
ocally  in  adipose  tissues  as  a  consequence  of  excessive
at  deposition,  and  is  later  reﬂected  in  increased  systemic
irculating  levels  of  proinﬂammatory  proteins.  Markers  of
bdominal  obesity  (e.g., waist  circumference)  seem  to  be
trongly  associated  with  inﬂammatory  markers,  and  a  reduc-
ion  in  the  adipose  tissue  mass  reduces  the  ability  of  adipose
issues  to  produce  proinﬂammatory  cytokines,  TNF, IL-6,
L-8,  and  leptin  [48—50]. Dental  diseases  such  as  peri-
dontitis  are  also  associated  with  high  levels  of  systemic
nﬂammation  [51],  a  signiﬁcant  predictor  of  inﬂammatory
llnesses,  such  as  cardiovascular  disease  [52,53]  and  dia-
etes  [54].  Moreover,  many  studies  show  that  peripheral
hronic  inﬂammation  increases  the  risk  of  mental  illness
3,4].  Depressive  patients  have  high  concentration  of  proin-
ammatory  cytokines  (i.e.,  IL-1, IL-6,  and  TNF-) in  blood
55].
In animal  models  using  rodents,  systemic  inﬂammation
nduces  ‘‘depression-like  behavior’’  such  as  anhedonia,
educed  appetite,  helplessness,  apathy,  and  social  with-
rawal  [56]. We  and  other  groups  showed  that  peripheral
njection  of  lipopolysaccharide  induced  anorexia  via  the
ncrease  of  hypothalamic  IL-1 and  IL-6  [57,58].  The  cir-
ulating  proinﬂammatory  cytokines  can  enter  the  central
ervous  system  in  areas  where  the  blood—brain  barrier  is
ncomplete,  or  can  be  transported  into  the  brain  tissues
y  carrier-mediated  mechanisms  across  the  blood—brain
arrier.  Therefore,  proinﬂammatory  cytokines  in  periph-
ral  blood  stream  communicate  with  the  brain  and  cause
he  activation  of  microglia  and  astrocytes.  In  the  case  of
icroglia,  TNF- activated  indoleamine  2,3-dioxygenase,  an
nzyme  enabling  the  production  of  kynurenine  from  trypto-
han,  the  origin  of  serotonin  [57].  This  resulted  in  decreasing
he  serotonin  synthesis  pathway  and  promoting  kynurenine
roduction,  itself  further  metabolized  into  quinolinic  acid.
uinolinic  acid  is  an  N-methyl-D-aspartate  (NMDA)  receptor
gonist,  which  induces  depression-like  behavior.  Therefore,
eripheral  inﬂammation,  mediated  by  obesity  or  oral  infec-
ious  diseases,  induces  the  decrease  of  serotonin  and  the
ncrease  of  neurotoxic  quinolinic  acid,  potentially  causing
ental  illness.  Therefore,  the  control  of  peripheral  inﬂam-
ation  is  crucial  for  maintaining  a  healthy  life.
. Conclusion
e  recently  deﬁned  PRIP  as  a  new  modulator  within  the
ipolysis  pathway,  which  negatively  regulates  the  phosphor-
lation  of  perilipin  and  HSL  in  WAT,  and  can  also  regulate
hermogenesis  in  BAT  via  fatty  acid  production.  Importantly,
eﬁciency  of  PRIP  in  mice  exhibited  anti-obesity  pheno-
ypes.  Therefore,  PRIP  represents  a  potential  therapeutic
arget  for  the  control  of  obesity.  Since  anti-obesity  ther-
py  can  reduce  the  risks  of  many  serious  health  disorders
tes  
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including  hypertension,  dyslipidemia,  type  2  diabetes,
coronary  heart  disease,  and  mental  disorders,  further  com-
prehensive  studies  of  PRIP  signaling  will  contribute  to  the
development  of  new  therapeutic  targets  aimed  at  tackling
excess  body  fat  accumulation  to  ensure  a  healthy  life.
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